CAS 1185194-18-6 rac Cinacalcet-[d3] - Isotope / BOC Sciences

General Information
Catalog: BLP-012701
CAS: 1185194-18-6
Molecular Formula: C22H19D3F3N
Molecular Weight: 360.43

General Information

Catalog: BLP-012701

CAS: 1185194-18-6

Molecular Formula: C22H19D3F3N

Molecular Weight: 360.43

Chemical Structure

Description	rac Cinacalcet-[d3] is the labelled analogue of Rac-Cinacalcet, which is a metabolite of Cinacalcet.
Synonyms	rac Cinacalcet-d3; α-(Methyl-d3)-N-[3-[3-(trifluoromethyl)phenyl)propyl]-1-napthalenemethanamine; N-(3-(3-(trifluoromethyl)phenyl)propyl)-1-(1-napthyl)ethylamine-d3
IUPAC Name	N-(2,2,2-trideuterio-1-naphthalen-1-ylethyl)-3-[3-(trifluoromethyl)phenyl]propan-1-amine
Related CAS	1025064-33-8 (unlabelled) 1095393-62-6 (unlabelled hydrochloride) 1185097-33-9 (hydrochloride)
Canonical SMILES	CC(C1=CC=CC2=CC=CC=C21)NCCCC3=CC(=CC=C3)C(F)(F)F
InChI	InChI=1S/C22H22F3N/c1-16(20-13-5-10-18-9-2-3-12-21(18)20)26-14-6-8-17-7-4-11-19(15-17)22(23,24)25/h2-5,7,9-13,15-16,26H,6,8,14H2,1H3/i1D3
InChI Key	VDHAWDNDOKGFTD-FIBGUPNXSA-N
Solubility	Soluble in Ethanol, Methanol, Water
Appearance	White Solid
Storage	Store at -20°C

rac Cinacalcet-[d3], a deuterium-labeled variant of Cinacalcet, utilized in the management of parathyroid-related disorders, offers a spectrum of applications. Delve into the key applications:

Pharmacokinetic Studies: Embracing rac Cinacalcet-[d3] in pharmacokinetic investigations unveils a realm of insight into drug metabolism within the body. The deuterium label acts as a beacon distinguishing the administered compound from endogenous substances and enabling precise assessment of absorption distribution metabolism and excretion dynamics. This data is pivotal for refining dosing strategies and enhancing therapeutic outcomes through a lens of unparalleled accuracy.

Drug Interaction Studies: Through the lens of rac Cinacalcet-[d3], scientists embark on explorations of potential drug-drug interactions, a critical endeavor in the landscape of pharmacology. The deuterated entity serves as a guide delineating Cinacalcet's metabolic pathways when co-administered with other pharmaceutical agents. This discernment is paramount in foreseeing adverse interactions and securing the efficacy and safety of combination therapies, heralding a new era of precision medicine.

Biomarker Studies: Grasping rac Cinacalcet-[d3] for biomarker exploration unravels a tapestry of insights into treatment effectiveness and disease progression. In conditions such as secondary hyperparathyroidism, the labeled compound serves as a cornerstone in deciphering metabolic shifts and uncovering pivotal biomarkers. These biomarkers, born out of intricate profiling enabled by the deuterated compound, pave the way for enhanced patient stratification and augmented treatment outcomes, redefining paradigms in precision medicine.